Sanofi Ebit from 2010 to 2024

SNY Stock  USD 48.49  0.23  0.47%   
Sanofi ADR EBIT yearly trend continues to be fairly stable with very little volatility. EBIT is likely to outpace its year average in 2024. During the period from 2010 to 2024, Sanofi ADR EBIT regression line of annual values had r-squared of  0.26 and arithmetic mean of  8,985,280,987. View All Fundamentals
 
EBIT  
First Reported
2000-12-31
Previous Quarter
1.5 B
Current Value
3.8 B
Quarterly Volatility
3.3 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sanofi ADR financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sanofi ADR's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.3 B, Interest Expense of 607 M or Selling General Administrative of 11.2 B, as well as many indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0232 or PTB Ratio of 1.44. Sanofi financial statements analysis is a perfect complement when working with Sanofi ADR Valuation or Volatility modules.
  
Check out the analysis of Sanofi ADR Correlation against competitors.
For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.

Latest Sanofi ADR's Ebit Growth Pattern

Below is the plot of the Ebit of Sanofi ADR over the last few years. It is Sanofi ADR's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sanofi ADR's overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Slightly volatile
   Ebit   
       Timeline  

Sanofi Ebit Regression Statistics

Arithmetic Mean8,985,280,987
Geometric Mean7,938,091,083
Coefficient Of Variation38.58
Mean Deviation2,604,654,099
Median8,015,623,138
Standard Deviation3,466,218,245
Sample Variance12014668.9T
Range14.1B
R-Value0.51
Mean Square Error9543676.5T
R-Squared0.26
Significance0.05
Slope397,031,714
Total Sum of Squares168205364.9T

Sanofi Ebit History

2024B
20237.8 B
202210.6 B
20218.4 B
202014.6 B
201915.1 B
201811.2 B

Other Fundumenentals of Sanofi ADR

About Sanofi ADR Financial Statements

Sanofi ADR investors use historical fundamental indicators, such as Sanofi ADR's Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sanofi ADR. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBIT7.8 BB
EBITDA12.6 B11.3 B
Ebt Per Ebit 0.91  1.12 
Ebit Per Revenue 0.17  0.22 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sanofi Stock Analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.